EN DE
Watch Foresee Pharmaceuticals Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Foresee Pharmaceuticals Co Ltd (6576) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Foresee Pharmaceuticals Co Ltd stock TWD 126, price TWD 73.90, upside +70.7%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006576002

FP Foresee Pharmaceuticals Co Ltd logo Thin data Nov 5, 2026

Foresee Pharmaceuticals Co Ltd

6576 · TWO
Cheap, value-trap risk

The stock costs 41% less than our calculation considers fair.

Fair value 126.16 TWD · Strongly undervalued
Low debt
Revenue last quarter +63% vs. a year ago.
Quality 48/100
Expensive Growth (revenue 5y +13.4 %/yr in TWD)
Thin margins · 4.8% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 15/100 · thin data
Thin data
Watch Foresee Pharmaceuticals Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

135.00 TWD 57.90 TWD Fair Value 126.16 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range 57.90 TWD – 135.00 TWD · fair‑value band 83.12 TWD – 157.70 TWD · the 73.90 TWD price screens below the 126.16 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Foresee Pharmaceuticals Co in your weekly email

Every Wednesday you see whether Foresee Pharmaceuticals Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe.

Show moreShow less

The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases.

Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases.

The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.

Stock analysis

Foresee Pharmaceuticals Co Ltd (6576) currently trades at 73.90 TWD, while our model-based Fair Value estimate is 126.16 TWD, implying the stock looks roughly 41% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 83.12 TWD (bear) to 157.70 TWD (bull), the price of 73.90 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Foresee Pharmaceuticals Co Ltd reported revenue of 431M TWD in FY2025 versus 226M TWD in FY2021, a compound +17.5%/yr. Reported net income was −883M TWD in FY2025.

Key figures

Market cap 11.6B TWD (≈ $355M) Small · P/E ratio 527.9 · P/S ratio 24.7 · EPS (TTM) 0.1400 TWD · Net margin 4.8% · Return on equity 2.0% · Return on assets (EBIT) −46.9% (5-year average) · Operating margin −58.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 71%, 6576 screens cheaper than that median.

Fair Value models

Bear 83.12 TWD Fair Value 126.16 TWD Bull 157.70 TWD
Price 73.90 TWD · Upside +70.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1201 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 2.53 TWD 3.84 TWD 4.80 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 2.53 TWD 3.84 TWD 4.80 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 89
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 31
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−209.1% (2020) → −199.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 6576, get fair value alerts →

Compare Foresee Pharmaceuticals Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside +70.7% · Top 25%
Profitability
Return on equity (12 months) 2.0% · Below median
Return on assets −67.4% · Bottom 25%
Net margin (12 months) 4.8% · Below median
Operating margin (12 months) −58.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 62.7% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 527.9× · Priciest 25%
P/B 12.52× · Priciest 25%
P/S (12 months) 24.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)8 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 6576
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs 6576
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,947 +2% vs 6576
Haleon plc HLN $9.14 $8.61 −6% vs 6576
Merck KGaA MRK €149.20 €109.18 −27% vs 6576
Galderma Group GALD CHF 190.65 CHF 109.86 −42% vs 6576
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 6576
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 6576
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs 6576
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 6576

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Foresee Pharmaceuticals Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Foresee Pharmaceuticals Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6576

Frequently asked questions

Is Foresee Pharmaceuticals Co Ltd (6576) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 126.16 TWD versus a price of 73.90 TWD, about +71% upside (undervalued).
What is the fair value of 6576?
Our model-based fair value for Foresee Pharmaceuticals Co Ltd is 126.16 TWD (as of Nov 5, 2026), built from audited fundamentals. The current price: 73.90 TWD.
What is the quality score of 6576?
Foresee Pharmaceuticals Co Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Foresee Pharmaceuticals Co Ltd (6576)?
Our model-based price target is the fair value of 126.16 TWD (as of Nov 5, 2026) from 1 valuation models. Cautious scenario 83.12 TWD, optimistic scenario 157.70 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Foresee Pharmaceuticals Co Ltd stock forecast for 2026?
Our models put fair value at 126.16 TWD, about +71% upside versus a price of 73.90 TWD (undervalued). Cautious scenario 83.12 TWD, optimistic scenario 157.70 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Foresee Pharmaceuticals Co Ltd (6576)?
Foresee Pharmaceuticals Co Ltd reported trailing-twelve-month revenue of about 471M TWD (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Foresee Pharmaceuticals Co Ltd (6576)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Foresee Pharmaceuticals Co Ltd it is 126.16 TWD per share (as of Nov 5, 2026), against a price of 73.90 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Foresee Pharmaceuticals Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 6576 trades below its calculated fair value: price 73.90 TWD, fair value 126.16 TWD, a gap of about +71% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6576?
No. The price is what the market pays today (73.90 TWD); the fair value is what the company's own numbers justify (126.16 TWD). For Foresee Pharmaceuticals Co Ltd the two are 52.26 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Foresee Pharmaceuticals Co Ltd worth?
The market values Foresee Pharmaceuticals Co Ltd at about 11.6B TWD (market capitalisation, as of Nov 5, 2026). Per share that is 73.90 TWD; our models calculate a fair value of 126.16 TWD per share.
What do the bullish and bearish scenarios say about 6576?
Our models span a range for Foresee Pharmaceuticals Co Ltd: cautious scenario 83.12 TWD, base 126.16 TWD, optimistic 157.70 TWD per share (as of Nov 5, 2026, price 73.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Foresee Pharmaceuticals Co Ltd (6576)?
Balance-sheet figures for Foresee Pharmaceuticals Co Ltd (as of Nov 5, 2026): return on equity 2.0%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 6576 from its 52-week high?
Foresee Pharmaceuticals Co Ltd trades at 73.90 TWD, about 15% below its 52-week high of 87.30 TWD and 3% above the low of 71.90 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 126.16 TWD is for.
Which stocks are comparable to Foresee Pharmaceuticals Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Foresee Pharmaceuticals Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 73.90 TWD, calculated fair value 126.16 TWD (+71%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6576 calculated?
We run Foresee Pharmaceuticals Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 126.16 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Foresee Pharmaceuticals Co Ltd currently trades 41% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Foresee Pharmaceuticals Co Ltd (6576)?
The closing price on Nov 9, 2026 was 73.90 TWD. Our model-based fair value is 126.16 TWD, about +71% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Foresee Pharmaceuticals Co Ltd right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (83.12 TWD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (83.12 TWD to 157.70 TWD) leaves room in how you read the outcome.

Key figures of Foresee Pharmaceuticals Co Ltd

How large is the market capitalisation of Foresee Pharmaceuticals Co Ltd (6576)?
The market capitalisation of Foresee Pharmaceuticals Co Ltd is 11.6B TWD (≈ $355M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Foresee Pharmaceuticals Co Ltd (6576)?
The price-to-earnings ratio of Foresee Pharmaceuticals Co Ltd is 527.9. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Foresee Pharmaceuticals Co Ltd (6576)?
The price-to-sales ratio of Foresee Pharmaceuticals Co Ltd is 24.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Foresee Pharmaceuticals Co Ltd (6576)?
Earnings per share at Foresee Pharmaceuticals Co Ltd are 0.1400 TWD (price ÷ EPS = P/E 527.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Foresee Pharmaceuticals Co Ltd (6576)?
The net margin of Foresee Pharmaceuticals Co Ltd is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Foresee Pharmaceuticals Co Ltd (6576)?
The return on equity (ROE) of Foresee Pharmaceuticals Co Ltd is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Foresee Pharmaceuticals Co Ltd (6576)?
On an EBIT basis the return on assets of Foresee Pharmaceuticals Co Ltd is −46.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Foresee Pharmaceuticals Co Ltd (6576)?
The operating margin of Foresee Pharmaceuticals Co Ltd is −58.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Foresee Pharmaceuticals Co Ltd (6576)?
Revenue at Foresee Pharmaceuticals Co Ltd is growing +62.7% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Foresee Pharmaceuticals Co Ltd (6576) generate?
The free cash flow of Foresee Pharmaceuticals Co Ltd is −858M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Foresee Pharmaceuticals Co Ltd in the live analysis

One click puts Foresee Pharmaceuticals Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.